Drugs / MY006
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07287033 | Dec 2025 → Apr 2027 expected | — | Mabylon AG | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-05-19 | Mabylon AG | Results Mabylon Reports Positive Phase Ia Results in MY006 Peanut Allergy Trial and Initiates Phase Ib Patient Part of the Study; Advances Tree Pollen Allergy Program MY010 toward Clinical Development mabylon.com ↗
Mabylon AG, a leader in the discovery and development of human-derived, half-life extended multi-specific antibodies, today reported preliminary positive Phase Ia data demonstrating a favorable safety profile of its lead candidate MY006 in an ongoing first-in-human trial. |
All press releases naming this drug 3 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MY006 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07287033 ↗ |
| Route | Subcutaneous | “MY006 administered by subcutaneous injection.” NCT07287033 ↗ |